Talampanel

Drug Profile

Talampanel

Alternative Names: GYKI-53773; LY-300164

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IVAX Drug Research Institute
  • Developer Teva Pharmaceutical Industries
  • Class Antiepileptic drugs; Antineoplastics; Neuroprotectants; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Dyskinesias; Epilepsy; Glioblastoma; Multiple sclerosis

Most Recent Events

  • 23 Jun 2010 Discontinued - Phase-II for Glioblastoma in USA (PO)
  • 08 Jun 2010 Teva Pharmaceutical Industries terminates phase II trial [NCT00982150] in Amyotrophic Lateral Sclerosis in the USA, Canada, EU and Israel
  • 18 May 2010 Interim efficacy and adverse event data from a phase II trial in Amyotrophic lateral sclerosis released by Teva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top